Back to Results
First PageMeta Content
Anilides / Ivacaftor / Phenols / Quinolones / Pancreas disorders / Cystic fibrosis / ΔF508 / VX-809 / Vertex Pharmaceuticals / Biology / Health / Genetics


PRIOR AUTHORIZATION POLICY Kalydeco® (ivacaftor tablets Vertex) To Initiate a Coverage Review, Call[removed]
Add to Reading List

Document Date: 2014-04-24 08:24:08

Open Document

File Size: 97,20 KB

Share Result on Facebook

City

Cambridge / /

Company

K. Vertex Pharmaceuticals / Vertex Pharmaceuticals Inc / /

Country

United States / /

Facility

National Library / /

IndustryTerm

treatment of cystic fibrosis / healthcare providers / /

MedicalCondition

TB / disease / cystic fibrosis transmembrane conductance regulator / cystic fibrosis / /

Organization

Cystic Fibrosis Foundation / Food and Drug Administration / National Newborn Screening and Genetic Resources Center / /

/

Position

Farrell PM / /

Product

May 2014 REFERENCES Kalydeco™ / REFERENCES Kalydeco™ tablets / /

ProvinceOrState

Pennsylvania / /

Technology

genotype / /

URL

http /

SocialTag